Oncotelic Therapeutics, Inc.
OTLC
$0.04
$0.001.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.33M | 490.50K | 65.70K | 100.80K | 32.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.33M | 491.00K | 66.00K | 101.10K | 31.50K |
| Operating Income | -2.33M | -491.00K | -66.00K | -101.10K | -31.50K |
| Income Before Tax | 361.84M | -1.11M | 210.40K | -364.30K | -654.50K |
| Income Tax Expenses | 111.55M | -- | -- | -- | -- |
| Earnings from Continuing Operations | 250.29M | -1.11M | 210.40K | -364.30K | -654.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 55.00K | 67.00K | 67.40K | 65.50K | 53.50K |
| Net Income | 250.35M | -1.05M | 277.90K | -298.70K | -600.90K |
| EBIT | -2.33M | -491.00K | -66.00K | -101.10K | -31.50K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.57 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.57 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 441.24M | 426.44M | 408.29M | 407.42M | 407.30M |
| Average Diluted Shares Outstanding | 441.24M | 426.44M | 452.81M | 407.42M | 407.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |